nach oben

AIDS and Behavior

Erschienen in:

13.03.2018 | Original Paper

Testing the Efficacy of Combined Motivational Interviewing and Cognitive Behavioral Skills Training to Reduce Methamphetamine Use and Improve HIV Medication Adherence Among HIV-Positive Gay and Bisexual Men

verfasst von: Jeffrey T. Parsons, Steven A. John, Brett M. Millar, Tyrel J. Starks

Erschienen in: AIDS and Behavior | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Prior research has identified subgroups of HIV-positive gay and bisexual men (GBM) based upon information, motivation, and behavioral skills (IMB) profiles related to HIV medication adherence and methamphetamine use. We conducted a randomized controlled trial of a combined motivational interview (MI) and cognitive behavioral therapy (CBT) intervention tailored specifically to the unique context of HIV-positive GBM, and tested whether IMB profiles moderated treatment effects. HIV-positive GBM (N = 210) were randomized to MI + CBT or an attention-matched education control. Both conditions resulted in reduced methamphetamine use, improved medication adherence (and higher CD4 and lower viral loads), and fewer acts of condomless anal sex at 3, 6, 9 and 12 months post-intervention. Furthermore, the MI + CBT condition achieved greater improvements in medication adherence for men who had greater barriers to change compared to similarly-classified men in the control condition, suggesting the importance of pre-intervention profiles for tailoring future interventions.

Centers for Disease Control and Prevention (CDC). HIV infection risk, prevention, and testing behaviors among men who have sex with men—National HIV Behavioral Surveillance, 20 U.S. Cities, 2014. 2016. http://www.cdc.gov/hiv/library/reports/surveillance/#panel2. Accessed 1 June 2017.

Center for Behavioral Health Statistics and Quality (CBHSQ). Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. 2016. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf. Accessed 1 June 2017.

Reback CJ, Fletcher JB, Shoptaw S, Grella CE. Methamphetamine and other substance use trends among street-recruited men who have sex with men, from 2008 to 2011. Drug Alcohol Depend. 2013;133(1):262–5.PubMedPubMedCentralCrossRef

Parsons JT, Lelutiu-Weinberger C, Botsko M, Golub SA. Predictors of day-level sexual risk for young gay and bisexual men. AIDS Behav. 2013;17(4):1465–77.PubMedPubMedCentralCrossRef

Pantalone DW, Bimbi DS, Holder CA, Golub SA, Parsons JT. Consistency and change in club drug use by sexual minority men in New York City, 2002 to 2007. Am J Public Health. 2010;100(10):1892–5.PubMedPubMedCentralCrossRef

Center for Behavioral Health Statistics and Quality (CBHSQ). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015.

Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253–62.PubMedCrossRef

Yu Q, Larson DF, Watson RR. Heart disease, methamphetamine and AIDS. Life Sci. 2003;73(2):129–40.PubMedCrossRef

Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. JINS. 2004;10(1):1–14.PubMed

10.

Carey C, Woods S, Rippeth J, Gonzalez R, Heaton R, Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav. 2006;10(2):185–90.PubMedCrossRef

11.

Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatr. 2006;63(1):90–100.PubMedCrossRef

12.

Solomon TM, Kiang MV, Halkitis PN, Moeller RW, Pappas MK. Personality traits and mental health states of methamphetamine-dependent and methamphetamine non-using MSM. Addict Behav. 2010;35(2):161–3.PubMedCrossRef

13.

Semple SJ, Patterson TL, Grant I. Binge use of methamphetamine among HIV-positive men who have sex with men: pilot data and HIV prevention implications. AIDS Educ Prev. 2003;15(2):133–47.PubMedCrossRef

14.

Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Group HNRC. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis. 2003;188(12):1820–6.PubMedCrossRef

15.

Carrico AW. Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV. Life Sci. 2011;88(21–22):940–7.PubMedCrossRef

16.

Langford D, Adame A, Grigorian A, et al. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. JAIDS. 2003;34(5):467–74.PubMed

17.

Soontornniyomkij V, Kesby JP, Morgan EE, et al. Effects of HIV and methamphetamine on brain and behavior: evidence from human studies and animal models. J Neuroimmune Pharm. 2016;11(3):495–510.CrossRef

18.

Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis. 2004;38:890–4.PubMedCrossRef

19.

Feldman M, Thomas J, Alexy E, Irvine M. Crystal methamphetamine use and HIV medical outcomes among HIV-infected men who have sex with men accessing support services in New York. Drug Alcohol Depend. 2015;147:266–71.PubMedCrossRef

20.

Massanella M, Gianella S, Schrier R, et al. Methamphetamine use in HIV-infected individuals affects T-cell function and viral outcome during suppressive antiretroviral therapy. Sci Rep. 2015;5:13179.PubMedPubMedCentralCrossRef

21.

Shoptaw S, Stall R, Bordon J, et al. Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study. Int J STD AIDS. 2012;23(8):576–80.PubMedPubMedCentralCrossRef

22.

Kumar S, Rao P, Earla R, Kumar A. Drug–drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Met. 2015;11(3):343–55.CrossRef

23.

Gavrilin MA, Mathes LE, Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol. 2002;8(3):240–9.PubMedCrossRef

24.

Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15(6):775–85.PubMedCrossRef

25.

Moore DJ, Blackstone K, Woods SP, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24(12):1504–13.PubMedPubMedCentralCrossRef

26.

Parsons JT, Kowalczyk WJ, Botsko M, Tomassilli JC, Golub SA. Aggregate versus day level association between methamphetamine use and HIV medication non-adherence among gay and bisexual men. AIDS Behav. 2013;17(4):1478–87.PubMedPubMedCentralCrossRef

27.

Vosburgh HW, Mansergh G, Sullivan PS, Purcell DW. A review of the literature on event-level substance use and sexual risk behavior among men who have sex with men. AIDS Behav. 2012;16(6):1394–410.PubMedCrossRef

28.

Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ. Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. JAIDS. 2016;71(5):551–7.PubMed

29.

Clark T, Marquez C, Hare CB, John MD, Klausner JD. Methamphetamine use, transmission risk behavior and internet use among HIV-infected patients in medical care, San Francisco, 2008. AIDS Behav. 2012;16(2):396–403.PubMedCrossRef

30.

Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78(2):125–34.PubMedCrossRef

31.

Reback CJ, Shoptaw S. Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. Addict Behav. 2014;39(8):1286–91.PubMedCrossRef

32.

Rawson RA, Marinelli-Casey P, Anglin MD, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99(6):708–17.PubMedCrossRef

33.

Reback CJ, Peck JA, Dierst-Davies R, Nuno M, Kamien JB, Amass L. Contingency management among homeless, out-of-treatment men who have sex with men. J Subst Abuse Treat. 2010;39(3):255–63.PubMedPubMedCentralCrossRef

34.

Garfein RS, Metzner M, Cuevas J, Bousman CA, Patterson T. Formative assessment of ARM-U: a modular intervention for decreasing risk behaviors among HIV-positive and HIV-negative methamphetamine-using MSM. Open AIDS. 2010;4:105–15.CrossRef

35.

Mimiaga MJ, Reisner SL, Pantalone DW, O’Cleirigh C, Mayer KH, Safren SA. A pilot trial of integrated behavioral activation and sexual risk reduction counseling for HIV-uninfected men who have sex with men abusing crystal methamphetamine. AIDS Patient Care STDS. 2012;26(11):681–93.PubMedPubMedCentralCrossRef

36.

Zule WA, Poulton WE, Coomes CM, et al. Results of a pilot study to reduce methamphetamine use and sexual risk behaviors among methamphetamine-using men who have sex with men (MSM) not currently in treatment. J Psychoactive Drugs. 2012;44(5):351–8.PubMedCrossRef

37.

Reback CJ, Grant DL, Fletcher JB, et al. Text messaging reduces HIV risk behaviors among methamphetamine-using men who have sex with men. AIDS Behav. 2012;7(16):1993–2002.CrossRef

38.

Lea T, Kolstee J, Lambert S, Ness R, Hannan S, Holt M. Methamphetamine treatment outcomes among gay men attending a LGBTI-specific treatment service in Sydney, Australia. PLoS ONE. 2017;12(2):e0172560.PubMedPubMedCentralCrossRef

39.

Wu E, El-Bassel N, McVinney LD, et al. Feasibility and promise of a couple-based HIV/STI preventive intervention for methamphetamine-using, Black men who have sex with men. AIDS Behav. 2011;15(8):1745–54.PubMedCrossRef

40.

DiClemente C, Prochaska J. Toward a comprehensive, transtheoretical model of change: stages of change and addictive behaviors. In: Miller WR, Heather N, editors. Applied clinical psychology. Treating addictive behaviors. New York: Plenum; 1998. p. 3–24.CrossRef

41.

Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results from the EDGE study. Drug Alcohol Depend. 2007;87(2):249–57.PubMedCrossRef

42.

Starks TJ, Millar BM, Lassiter JM, Parsons JT. Preintervention profiles of information, motivational, and behavioral self-efficacy for methamphetamine use and HIV medication adherence among gay and bisexual men. AIDS Patient Care STDs. 2017;31(2):78–86.PubMedPubMedCentralCrossRef

43.

Fisher JD, Fisher WA. Changing AIDS-risk behavior. Psychol Bull. 1992;111(3):455–74.PubMedCrossRef

44.

Horvath KJ, Smolenski D, Amico KR. An empirical test of the information-motivation-behavioral skills model of ART adherence in a sample of HIV-positive persons primarily in out-of-HIV-care settings. AIDS Care. 2014;26(2):142–51.PubMedCrossRef

45.

John SA, Walsh JL, Weinhardt LS. The information-motivation-behavioral skills model revisited: a network-perspective structural equation model within a public sexually transmitted infection clinic sample of hazardous alcohol users. AIDS Behav. 2017;21(4):1208–18.PubMedCrossRef

46.

Walsh JL, Senn TE, Scott-Sheldon LA, Vanable PA, Carey MP. Predicting condom use using the Information-Motivation-Behavioral Skills (IMB) model: A multivariate latent growth curve analysis. Ann Behav Med. 2011;42(2):235–44.PubMedPubMedCentralCrossRef

47.

Stout R, Wirtz P, Carbonari J. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol. 1994;2(S):70–5.CrossRef

48.

Sobell MB, Sobell LC. Problem drinkers: guided self-change treatment. New York: Guilford Press; 1993.

49.

Carey MP, Carey K, Maisto S, Gordon C, Weinhardt L. Assessing sexual risk behaviour with the Timeline Followback (TLFB) approach: continued development and psychometric evaluation with psychiatric outpatients. Int J STD AIDS. 2001;12(6):365–75.PubMedPubMedCentralCrossRef

50.

Weinhardt LS, Carey MP, Maisto SA, Carey KB, Cohen MM, Wickramasinghe SM. Reliability of the timeline follow-back sexual behavior interview. Ann Behav Med. 1998;20(1):25–30.PubMedPubMedCentralCrossRef

51.

Hoyle RH, editor. Handbook of structural equation modeling. New York: The Guilford Press; 2012.

52.

Kline RB. Principles and practice of structural equation modeling. New York: The Guilford Press; 2011.

53.

McDonald RP, Ho MH. Principles and practice in reporting structural equation analyses. Psychol Methods. 2002;7(1):64–82.PubMedCrossRef

54.

Satorra A, Bentler PM. A scaled difference chi-square test statistic for moment structure analysis. Psychometrika. 2001;66(4):507–14.CrossRef

55.

Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack-cocaine users. Drug Alcohol Depend. 2011;116:177–87.PubMedPubMedCentralCrossRef

56.

57.

Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun. 2008;22(8):1257–62.PubMedPubMedCentralCrossRef

58.

Carrico AW, Johnson MO, Moskowitz JT, et al. Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy. Psychosom Med. 2007;69(8):785–92.PubMedCrossRef

59.

Carrico AW. Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV. Life Sci. 2010;88(21):940–7.PubMed

60.

Toussi SS, Joseph A, Zheng JH, Dutta M, Santambrogio L, Goldstein H. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses. 2009;25(11):1117–21.PubMedPubMedCentralCrossRef

61.

Fairbairn N, Kerr T, Milloy MJ, Zhang R, Montaner J, Wood E. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav. 2011;36(7):762–3.PubMedPubMedCentralCrossRef

62.

Halkitis PN, Parsons JT, Stirratt MJ. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. J Homosexuality. 2001;41(2):17–35.CrossRef

63.

Carroll RT. Daily living, functional health, and adherence to anti-viral drug regimens in young adult, HIV+ methamphetamine users. In: AIDS 2006—XVI international AIDS conference, Toronto, Canada. 2006.

64.

Drisko JW. Common factors in psychotherapy outcomes: meta-analytic findings and their implications for practice and research. Fam Soc. 2004;85(1):81–90.CrossRef

65.

Reback CJ, Peck JA, Feltcher JB, Nuno M, Dierst-Davis R. Lifetime substance use and HIV sexual risk behaviors predict treatment response to contingency management among homeless, substance-dependent MSM. J Psychoact Drugs. 2012;44(2):166–72.CrossRef

66.

Clifford PR, Maisto SA, Davis CM. Alcohol treatment research assessment exposure subject reactivity effects: part I. Alcohol use and related consequences. J Stud Alcohol Drugs. 2007;68(4):519–28.PubMedCrossRef

67.

Clifford PR, Davis CM, Maisto SA. Alcohol treatment research assessment exposure subject reactivity effects: part II. Treatment engagement and involvement. J Stud Alcohol Drugs. 2007;68(4):529–33.PubMedCrossRef

68.

Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Belmont: Wadsworth; 2002.

69.

Solomon TM, Halkitis PN, Moeller RW, Pappas MK. Levels of methamphetamine use and addiction among gay, bisexual, and other men who have sex with men. Addict Res Theory. 2012;20(1):21–9.CrossRef

70.

Semple SJ, Strathdee SA, Zians J, McQuaid JR, Patterson TL. Drug assertiveness and sexual risk-taking behavior in a sample of HIV-positive, methamphetamine-using men who have sex with men. J Subst Abuse Treat. 2011;41:265–72.PubMedPubMedCentralCrossRef

Titel: Testing the Efficacy of Combined Motivational Interviewing and Cognitive Behavioral Skills Training to Reduce Methamphetamine Use and Improve HIV Medication Adherence Among HIV-Positive Gay and Bisexual Men
verfasst von: Jeffrey T. Parsons
Steven A. John
Brett M. Millar
Tyrel J. Starks
Publikationsdatum: 13.03.2018
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 8/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-018-2086-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

A Randomized Pilot Trial of a Novel Behavioral Intervention for Chronic Pain Tailored to Individuals with HIV

Late Presentation of HIV Infection in the Netherlands: Reasons for Late Diagnoses and Impact on Vocational Functioning

Adherence to Highly Active Antiretroviral Therapy Among Children in Ethiopia: A Systematic Review and Meta-analysis

A Conceptual Model of Dyadic Coordination in HIV Care Engagement Among Couples of Black Men Who Have Sex with Men: A Qualitative Dyadic Analysis

Sex Trade and Health Care Utilization Among People Living with HIV/AIDS

HIV-Related Healthcare Needs and Access Barriers for Brazilian Transgender and Gender Diverse People